
COVIDã®èµ·æºã«é¢ãããã¡ãŠãã®ãåŠå®ãšæ¬ºçããçç©å µåšã®äž»èŠå¹¹éšãå ¬ã«éé£
å èšäºã¯ãã¡ããã/Click here to read the original article.
調æ»ãžã£ãŒããªã¹ããããŒã«ã»Dã»ãµãã«ãŒãšã®ã€ã³ã¿ãã¥ãŒã®äžã§ãçç©é²è¡é¢ä¿è ã®ãããŒãã»ã«ãã¬ãã¯å士ã¯ãã¢ã³ãœããŒã»ãã¡ãŠãå士ã®ãããªäž»èŠå¹¹éšããProximal Originãè«æãæžãããŠã€ã«ã¹åŠè ãã¡ã¯ãCOVID-19ãç 究宀ã§çãŸããå¯èœæ§ãé«ãããšãç¥ã£ãŠããããèªåãã¡ã®ãã£ãªã¢ãšè³éãå®ãããã«å€å žçãªãæ å ±æäœãæŠè¡ã䜿ã£ããšäž»åŒµããã
COVID-19ãã³ãããã¯éå§æã«ãã©ã³ãæ¿æš©äžã§å»çã»å ¬è¡è¡ç察çã§éèŠãªåœ¹å²ãæãããçç©é²è¡ã®ç¬¬äžäººè ããã¢ã³ãœããŒã»ãã¡ãŠãå士ãå«ãçŸã»å æ¿åºé«å®ãCOVID-19ã®èµ·æºãããã£ãŠåœæ°ãã誀ã£ãæ¹åã«èªå°ãããŠãããšäž»åŒµããã
調æ»ãžã£ãŒããªã¹ããããŒã«ã»Dã»ãµãã«ãŒæ°ãšã®ã€ã³ã¿ãã¥ãŒã®äžã§ããããŒãã»ã«ãã¬ãã¯å士ã¯ããã¡ãŠãåç±³åœç«ã¢ã¬ã«ã®ãŒææçç ç©¶ææé·ããã©ã³ã·ã¹ã»ã³ãªã³ãºåç±³åœç«è¡çç ç©¶æïŒNIHïŒæé·ããã®ä»ã®æ¿åºé«å®ãäž»èŠãªãŠã€ã«ã¹åŠè ãããŠã€ã«ã¹ã®èµ·æºã«ã€ããŠãåŠå®ãšæ¬ºçããè¡ã£ãŠããããšã瀺åããã
ã«ãã¬ãã¯æ°ã¯COVID-19ã®ãã³ãããã¯ãå§ãŸã£ãæãæºåã»å¯Ÿå¿æ åœæ¬¡å®è£ãšããŠæŠç¥çæºåã»å¯Ÿå¿å±ïŒASPRïŒãææ®ããããã®åŸã圌ã¯äžé¢å§å¡äŒã®ææ®ãå·ãã2022幎10æããã³ãããã¯ã®èµ·æºã«é¢ããäžéå ±åæžãçºè¡šããã
ãããšã¯å¥ã«ããµãã«ãŒã¯ãåœæ å ±ã¯ããã¯ã«ããžã®2023幎12æ22æ¥ã®æçš¿ã§ããç¥ãæš©å©ãïŒUSRTKïŒã仿åãã«çºè¡šããæ°ããææžãåæããã
USRTKã«ããã°ããããã®ææžã¯ããã¢ã¡ãªã«ã®ç ç©¶è ããCOVID-19ãã³ãããã¯ã®å幎ã«ãåœé²ç·çãããç·©ãå®å šåºæºã®äžã§ãæŠæŒ¢ã§å±éºæ§ã®é«ãã³ãããŠã€ã«ã¹ç ç©¶ãè¡ãæå³ãé ããŠãããããšã瀺ããŠããã
ãµãã«ãŒæ°ã¯ããã£ãã§ã³ããŒãèªãšã®ã€ã³ã¿ãã¥ãŒã®äžã§ããããã®ææžã¯ãããèªäœãCOVID-19ãäžåœã®æŠæŒ¢ãŠã€ã«ã¹ç ç©¶æããçãŸãããšãã蚌æ ã§ã¯ãªãããã®ç ç©¶æã§ç©è°ãããããŠããæ©èœç²åŸç ç©¶ã«é¢äžãã人ã ãäžæ£ãåãããšãã蚌æ ã§ãããšè¿°ã¹ãã
ãµãã«ãŒã¯èšãããããã¯ããããã®äººã ãåãã€ããŠããããšã瀺ãããäžã€ã®äŸã§ããæŠæŒ¢ã®ç ç©¶æã®äºæ ã瀺ãæã匷åãªèšŒæ ã¯ãç ç©¶è ãã¡ãæŠæŒ¢ã§äœãããŠãããã«ã€ããŠåãã€ããŠãããã¹ãŠã®äŸã§ããããã蚌æ ã ã
ãµãã«ãŒã¯ããã㯠ãç§åŠçäžæ£è¡çºã®ææ°ã®äŸã«éããªã ããšæžããã2023幎12æ22æ¥ã®æçš¿ã§ããµãã«ãŒã¯ããã®ãããªäžæ£è¡çºã¯ã¡ãã£ã¢ã®ç§åŠã©ã€ã¿ãŒã«ãã£ãŠå©ããããŠãããšè¿°ã¹ãã
ãç ç©¶è ãšãã®ãããã®ç§åŠã©ã€ã¿ãŒããç§åŠçæš©åšããžã£ãŒããªãºã çæš©åšãšç§°ãããæš©åšãã声æãç¢ºä¿¡ãææžã§èŠãé ããšããããŠãããåã§ããããšããã¬ããšããã®ã¯ã倧æµè¡ã®å®èª¬ã«ãªã£ãŠããããšåœŒã¯æžããŠããã
æ å ±æäœã«é¢äžãããã¡ãŠãã
ãµãã«ãŒæ°ã«ããã°ããã«ãã¬ãã¯æ°ã¯30æ°å¹Žéãã¢ã«ãã¡ãããé ã«äžŠãã ããŸããŸãªæ©é¢ã§çç©å µåšå¯Ÿçã«æºãã£ãŠããã
圌ã®ç£èŠäžã§2022幎10æã«çºè¡šãããç±³äžé¢ã®äžéå ±åæžã¯ãããããããªã«ïŒãããã£ã»ãã§ã¢ã«ããç¬å èšäºãšãªããåŸã«2700èªã®ç·šéåŸèšãä»ãå ããããç©è°ãéžããããšã¿ãã«ãŒã¯æžããŠããã
2022幎10æ28æ¥ä»ã§ããããããªã«ãã«æ²èŒãããå ±åæžã«ããã°ãããã³ãããã¯ã®çºçã«é¢ããçæã®äžå¿ãšãªã£ãæŠæŒ¢ã®ç ç©¶æã¯ãç¥ãããŠãããããã¯ããã«åé¡ãå€ãã£ã ããšããã
ãã®åŸãç§åŠçã®äžéšããæ¹å€ãèµ·ããããã®çµæãProPublicaã¯2022幎11æ30æ¥ããç§åŠè ãäžåœãªãã¶ãŒããŒããã®ä»ãäžé¢ããŒã ã®èª¿æ»çµæãšããã«é¢ããæã ã®å ±éã«çåãåãã ããšããç·šéæ³šãçºè¡šããã
ProPublicaã®ç·šéè ã¯ãèšäºã«ã远å çãªæèã远å ããããèšäºã®åæã«ã¯åãã«è¶³ããªã2ã€ã®äºå®èª€èªãç¹å®ããããããä¿®æ£ãããããããProPublicaã¯ããæã ã®æ€èšŒã®çµæããã®èšäºãšããããŸãšããå ±éå šäœãå¥å šã§ããããšã確èªãããïŒ
"2019幎ãWIVïŒæŠæŒ¢ãŠã€ã«ã¹ç ç©¶æïŒã¯ãããã®ç§åŠè ãã¡ãæ¥çžŸã®ãã¬ãã·ã£ãŒã«çŽé¢ããäžæ¹ã§ãæ·±å»ãªå®å šæ§ã®åé¡ã«åãçµãã§ããããšã¯äŸç¶ãšããŠæããã§ãããäžéå ±åæžã«ããã°ãå±éºãªã³ãããŠã€ã«ã¹ç ç©¶ã¯ãæå€§éã®çç©åŠçå°ã蟌ãã®å®å šå¯Ÿçãæ¬ åŠããç ç©¶æã§è¡ãããŠããã...
ã...WIVã§ãã€ãªã»ãã¥ãªãã£ãŒéåãçºçãããã³ãããã¯ã®ç«çš®ãšãªã£ãå¯èœæ§ã¯äŸç¶ãšããŠé«ããã
ãµãã«ãŒæ°ã«ããã°ãã«ãã¬ãã¯æ°ã¯ã以å㯠ãã»ãšãã©æ°Žé¢äžã§åããŠãã ãããä»ã§ã¯å®åæ©æ§ããå§¿ãçŸãããé£éŠæ¿åºã®ç§åŠè ãšåœŒããè³éãæäŸãããŠã€ã«ã¹åŠè ãã¡ã¯ããã³ãããã¯ãæŠæŒ¢ã®ç 究宀ïŒã¢ã¡ãªã«ã®è³éã§éå¶ãããŠããç 究宀ïŒã§å§ãŸã£ããšãã蚌æ ãé èœããåœæ°ã誀ã£ãæ¹åã«èªå°ãã ããšäž»åŒµããŠããã
Kadlecã¯Thackerã«ãFauciãšCollinsã¯èªåãã¡ã®è©å€ãšé£éŠæ¿åºããã®ç ç©¶è³éãå®ãããã£ããšèªã£ãã
ãµãã«ãŒã«ããã°ãããããã®ç ç©¶è ã®åæ©ã¯æããã§ãããã
ãã®ç®çãéæããããã«ãã«ãã¬ãã¯ã«ããã°ãããã¹ãã£ã¬ã¯ã·ã§ã³ ããè¡ãããç 究宀ãªãŒã¯èª¬ã軜èŠããäžéã®é¢å¿ãããããããšãããšã®ããšã§ããã
ãç§ã«ã¯æ å ±æäœã«ããèŠããŸããã人ã ãé ãããŠããããããŠã圌ãã¯ããŸããŸãªææ®µã䜿ã£ãŠãããè¡ã£ããé èœå·¥äœãšããèŠæ¹ãã§ãããã
ã«ãã¬ãã¯ã¯ã2020幎2æã®æç¹ã§ããã¡ãŠããšäž»èŠãªãŠã€ã«ã¹åŠè ãã¡ã¯ããããã¯å®éšå®€ã§ã®åºæ¥äºã§ãã£ãå¯èœæ§ãããããšå ã ã«é»åã¡ãŒã«ã§èªããŠãããšææããã
圌ã¯ãŸãã2020幎3æã«ããã€ãã£ãŒã»ã¡ãã£ã·ã³ãèªã«æ²èŒããããä»ãšãªã£ãŠã¯æåãªè«æãSARS-CoV-2ã®è¿æ¥èµ·æºãïŒ"Proximal Origin"ïŒã®èè ã®äžäººã§ãããã«ãªãã©ã«ãã¢ã«æ¬æ ã眮ãã¹ã¯ãªããã¹ç ç©¶æã®å ç«åŠã»åŸ®çç©åŠææã¯ãªã¹ãã£ã¢ã³ã»ã¢ã³ããŒã»ã³å士ã«ã€ããŠãèšåããã
2023幎7æã®ç±³åœäžé¢ã®å ±åæžã«ããã°ããProximal Originãè«æã¯ãç 究宀ããã®æµåºä»®èª¬ã軜èŠããããŠã€ã«ã¹ãç 究宀ããæµåºããå¯èœæ§ã瀺åããè ã«ãé°è¬è«è ãã®ã¬ããã«ã貌ãããã«äœ¿çšããããå ±åæžã«ããã°ããã¡ãŠããšã³ãªã³ãºã¯ãã®è«æã®æ§æ³ãèµ·èãåºçã«å人çã«é¢äžããŠããã
ã«ãã¬ãã¯ããµãã«ãŒã«èªã£ããšããã«ããã°ããã¡ãŠããšãã®è«æã®å ±èè ã§ããã¢ã³ããŒã»ã³ãå«ãäœäººãã®ç§åŠè ã¯ã2020幎2æ1æ¥ã«äº€ããããäžé£ã®é»åã¡ãŒã«ãšé»è©±ã®äžã§ãCOVID-19ãå·¥äœãããå¯èœæ§ãããããšãå ã ã«èªããŠããããã§ãããã«ãã¬ãã¯ããããåãåã£ããšã®ããšã§ããã
ãã¡ãŠãã®å ¬åŒå£°æãCOVID-19ãšç 究宀ããã®æµåºãšã®é¢é£ãåŠå®ããŠããããšã«è§Šããã«ãã¬ãã¯ã¯ããèšã£ãã
ããã¡ãŠãã¯ãžã§ã¬ããŒã»ãã¡ãŒã©ãŒïŒãŠã§ã«ã«ã ã»ãã©ã¹ãã®åœæã®è²¬ä»»è ïŒãšãã®ä»²éã§å¥ã®ã°ã«ãŒããäœã£ãããããŠããã®ã°ã«ãŒãã¯å ã ã§ã¯æžå¿µããããšèšããªãããå ¬ã®å Žã§ã¯å®éšå®€ã§ã®äºæ ã¯èµ·ããåŸãªããšèšãã®ã§ãããšåœŒã¯èšã£ãã
ã«ãã¬ãã¯æ°ã¯ããã¡ãŠãæ°ã ãæ¬ç©ã®ãªãã¬ãŒã¿ãŒ ããšåŒã³ãèªåãšèªåã®ç ç©¶æã®è©å€ã«æ¢åŸæš©çãæã£ãŠããã圌ãã¯åã£ãŠãåããªãé¢ä¿ã«ããã
NIHãšããã¡ãŠããšã³ãªã³ãºãšãããèªç±ã§ç§åŠçãªç ç©¶ãã€ãŸãã²ã€ã³ã»ãªãã»ãã¡ã³ã¯ã·ã§ã³ç ç©¶ãæå±ããäºäººã«å¯Ÿãã颚è©ãªã¹ã¯ã ãšæããŸãã
ãNIHãè³éæäŸããæ©èœç²åŸç ç©¶ãä»åã®äºæ ãæããã®ã§ãããããšã«ãã¬ãã¯æ°ã
ãã¡ãŒã©ãŒãã³ãªã³ãºããã¡ãŠãã®3人ã®é°è¬ããäœãèµ·ãã£ãŠããã®ãã®äžå¿ã§ããããã ããšåœŒã¯ä»ãå ããã
ãã¡ãŠãã¯ã1æ8æ¥ãš9æ¥ã®2æ¥éãç±³äžé¢ã³ãããŠã€ã«ã¹æµè¡ã«é¢ããç¹å¥å°å§å¡äŒã«åºåžããããã³ãããã¯äžããããŠãã³ãããã¯åŸã«çããæ°ã ã®è«äº ãã«ã€ããŠããŒãèµ·ããã€ã³ã¿ãã¥ãŒãåããäºå®ã§ããã
圌ã¯ä»å¹ŽåŸåã«å°å§å¡äŒã§å ¬åŒã«èšŒèšããäºå®ã§ããã
ã³ãªã³ãºã¯ãããã«ç®ç«ã€åœ¹å²ããæããã
ã«ãã¬ãã¯ã«ããã°ãã³ãªã³ãºã¯ãã¡ãŠã以äžã«éèŠãªåœ¹å²ãæãããŠãããšããã
ããã¡ãŠããé»å¹ã ãšæãããã§ãããããã³ãªã³ãºãé»å¹ãããããŸãããã³ãªã³ãºã¯ãŸã ãã¯ã€ãããŠã¹ã§åããŠããããŸã 倧統é ã®ã¢ããã€ã¶ãŒã§ãã
ã«ãã¬ãã¯ã«ããã°ãã³ãªã³ãºã¯åœŒãšASPRãå šç±³ç§åŠã»å·¥åŠã»å»åŠã¢ã«ãããŒãšååãã2020幎1æã«ïŒSARS-Cov-2ã®ïŒéºäŒåé åãäœã瀺ãããã調ã¹ãããšããã®ãæ¢ããããšãããããšããã
圌ã¯ç§ã«ããèšã£ããããªããããªããšãïŒãã«ãã¬ãã¯ã¯ããä»ãå ããããã§ãã圌ã¯å šç±³ã¢ã«ãããŒãNIHã®ç¬å£å Žã®ããã«æããŠãããç§ã¯åœŒã«ããã³ãããã¯å¯Ÿçã§ç§ã®ããã«ã¢ã«ãããŒã«ãéãæã£ãŠä»äºãããŠããã£ãŠããããšãæãåºãããªããã°ãªããŸããã§ããã
ã«ãã¬ãã¯ã«ããã°ãã¢ã³ããŒã»ã³ã®ãããªç§åŠè ãã¡ã¯ããNIHããè³éãåŸãŠæ©èœç²åŸç ç©¶ãè¡ãããã®äžéšã¯äžåœãšå ±åã§è¡ã£ããã®ã§ããããã³ãããã¯ã®åæãããç 究宀ããã®æµåºã®å¯èœæ§ã瀺ã蚌æ ãåºå§ããŠãããšããã
ã«ãã¬ãã¯ã«ããã°ãCOVID-19ã«å¯Ÿããã¯ã¯ãã³ã®ç¹èš±ãæåã«ååŸããã®ã¯äžåœäººæ°è§£æŸè»ã®ç§åŠè ã§ãã¯ã¯ãã³åŠè ã§ããã£ãåšè£æ³ã§ãã£ãã
ã圌ãCOVIDã¯ã¯ãã³ã«ã€ããŠçºè¡šããç¹èš±ãšå 容ãèŠãã°ã圌ãéåžžã«æ©ãææããCOVIDãŠã€ã«ã¹ã®ç ç©¶ãå§ããªããã°ãªããªãã£ãããšãããã«ããããã
ããããŠåœŒã¯æŠæŒ¢ãŠã€ã«ã¹ç ç©¶æã§ããŠã¹ã䜿ã£ãåç©å®éšãè¡ã£ãŠããããã ã圌ã¯2019幎ã®11æã«WIVãšå ±åã§è«æãçºè¡šãããé©ããããšã«ããã®ã¢ãŠããã¬ã€ã¯ã¯æŠæŒ¢ã§èµ·ããŠãããã
Kadlecã¯å ããŠïŒ
ããããåç©ããèªç¶ã«ãããããããã®ã ãšãã説åŸåã®ããè°è«ã¯ã§ããªãã圌ããããããšããŠããã®ã¯ã人ç£å ±éææçã§ãããšãã䞻匵ã§ããããããè£ä»ãã蚌æ ã¯ãªããã
ãç§ãæã£ãŠãã蚌æ ã¯ãäžåœã®CDCïŒçŸç 管çäºé²ã»ã³ã¿ãŒïŒã®ãã£ã¬ã¯ã¿ãŒã§ãã£ããžã§ãŒãžã»ã¬ãªã«ãããã®ã§ã圌ã¯ãã®ãŠã€ã«ã¹ãåžå Žããã®ãã®ã§ã¯ãªããšçºè¡šããŠãããã
人ç£å ±éææèª¬ã ããŠã§ããã»ããŒã±ãããèª¬ãæšé²ãç¶ããç§åŠè ãããã®ã¯ãªãããšã®è³ªåã«å¯Ÿããã«ãã¬ãã¯æ°ã¯ ãäžåœã§ããè²æ©ãã ããã®èª¬ã ã赀信å·ããšåŒã³ããã®ãããªã¡ãã»ãŒãžã¯ ãæ å ±æäœã®ããã«èŠãã ããšè¿°ã¹ãã
ããã¹ãã£ã¬ã¯ã·ã§ã³ãããã¯åŠå®ãšæ¬ºçã®ãããªãã®ã ããšã«ãã¬ãã¯ã¯èšããã©ãããã°ããããã¯ãããã ããšããé»è©±ãããå察㫠ãç ç©¶æã§ããå¯èœæ§ã¯ãªã ããšèšããã®ããããã説æã§ããã°ããã®ã ã......
æ¿åºæ©é¢ããåçãåŸãã®ã¯ãæ¯ãæãããããªãã®
ã«ãã¬ãã¯ã¯ã2020幎2æ1æ¥ã«ãã¡ãŠããã³ãªã³ãºãã¢ã³ããŒã»ã³ããã¡ãŒã©ãŒããéã£ãã¡ãŒã«ã®åä¿¡è ã§ãã£ãããèªãã èŠãã¯ãªããšèªã£ãã
ãåœæã¯......ãã³ãããã¯ãã©ã®ããã«å§ãŸã£ãããè§£æããããšã¯ãç§ã®å°éåéã§ã¯ãããŸããã§ãããç§ã¯å¯Ÿçãç é¢ã·ã¹ãã ã®ä¿å šãPPEã®é åžã«éäžããŠããŸãããã
åœæã圌ãæå±ããŠããASPRã¯ãå šç±³ã¢ã«ãããŒã«ãïŒSARS-CoV-2ã®ïŒéºäŒåé åã調ã¹ãŠãäžã®äžã«åºåã£ãŠããèåç¡çšœãªæ¶æž¬ã®ããã€ããåãæšãŠãŠã»ããããšäŸé Œãããã圌ãã®åçã¯ããã£ãšæ å ±ãå¿ èŠã ããšãããã®ã ã£ãã
ã«ãã¬ãã¯æ°ã¯ãåŸã«äžé¢HELPïŒä¿å¥ã»æè²ã»åŽåã»å¹ŽéïŒå§å¡äŒãçããŠCOVID-19ã®èµ·æºã調æ»ããéããæŠæŒ¢ã§èµ·ãã£ããšæãããããšãšNIHã®è³éæäŸãçŽæ¥çµã³ã€ããããšã¯ã§ããªãã£ã ããšèªã£ãã
ãµãã«ãŒæ°ã¯ããã£ãã§ã³ããŒãçŽã«ãHELPã®å ±åæžã¯NIHã«ã€ããŠã¯ã»ãšãã©è§ŠããŠãããããã¡ãŠããæ©èœç²åŸç ç©¶ã«ã€ããŠãè§ŠããŠããªãããäžåœã«å€ãã®è²¬ä»»ãè² ãããŠãããšèªã£ãã
ããã®å ±åæžã¯ãäžåœã«çå ãåããããã®å€§ããªãã¹ãã£ã¬ã¯ã·ã§ã³ã§ãããäœãèµ·ãã£ãŠããã®ããè§£æããå¯äžã®æ¹æ³ã¯ãäžåœãããéææ§ãå¢ãããã©ããã§ãããäžåœãéææ§ãé«ããããšããªãããšã¯ããã£ãŠããã®ã ãããã
NIHãCDCã®ãããªå ¬è¡è¡çæ©é¢ã¯ãCOVID-19ã®èµ·æºãè§£æããããšã«ã¯é¢äžããŠããªããšææããäžã§ãã«ãã¬ãã¯æ°ã¯æ¬¡ã®ããã«è¿°ã¹ãã...æ å ±ã³ãã¥ããã£ãšç§åŠã³ãã¥ããã£ã®éã«ã¯ãåž°å±ãè¡ãåªåãäž»å°ãã責任ãè² ãè ãããªããã°ãªããªããšããèãããã£ãã
ç§ã®èšæ¶ãæ£ãããã°ãããã¯æçµçã«åœåçã«å§ããããããããã圌ããç¥ã£ãŠããç§åŠãšã¯äœãªã®ããæ å ±æ©é¢ãšã¯äœãªã®ãïŒ
圌ã¯ãNIHãæ°äž»å ã®æ¿æ²»å®¶ãäžé¢ãäžé¢ã®æ å ±å§å¡äŒã®ãããªçµç¹ããçããåŸãããšã¯ã"æ¯ãæã "ãããªãã®ã ãšä»ãå ãã
æ¿åºè³éã«ããæ©èœç²åŸç ç©¶ã®æ°ããªèšŒæ
ã«ãã¬ãã¯ã«ããã°ããã®ãããªã³ãããŠã€ã«ã¹ã®ç ç©¶ã¯ãCOVID-19ãåºçŸãããã£ãšåããé²ããããŠããã
2015幎ã«ããã€ãã£ãŒãèªã«ããè«æïŒã¬ã¿ãŒïŒãçºè¡šãããããã«ã€ããŠ2ã€ã®èšæ£ãåºããããããã¯ã©ã«ãã»ããªãã¯ãšã·ãŒã»ãžã§ã³ãªã®è«æã§ã»ã»ã»ãNIHã®ãã¡ãŠãã®ç ç©¶æããè³éæŽå©ãåããŠãããæ£èª€è¡šã«ã¯USAIDïŒç±³åœåœééçºåºïŒã®PREDICTããã°ã©ã ãããè³éæŽå©ãåããŠããããšã远å ãããŠãããã
ãã®æžç°¡ã¯ã"A SARS-like cluster of circulating bat coronavirus shows potential for human emergence "ãšé¡ããã2020幎3æã«ç·šéè ã®æ³šéãå ããããŠããïŒ ããã®è«æããCOVID-19ã®åå ã§ããæ°åã³ãããŠã€ã«ã¹ã人工çã«äœããããšããæªæ€èšŒã®èª¬ã®æ ¹æ ãšããŠäœ¿ãããŠããããšã¯æ¿ç¥ããŠãããç§åŠè ãã¡ã¯ããã®ã³ãããŠã€ã«ã¹ã®çºçæºã¯åç©ã§ããå¯èœæ§ãæãé«ããšä¿¡ããŠãããã
ãµãã«ãŒæ°ã¯ãUSRTKã®ææžå ¬éã®äžç°ãšããŠãå æåæ§ã®äŸãçŸãããšæžããŠããããã®ææžã«ããã°ãç±³åœã® ããŠã€ã«ã¹åŠè ãšæŠæŒ¢ã®ç ç©¶è ã¯ã2018幎ã®DEFUSEãšåŒã°ãã婿éã«ãããŠãå±éºãªãŠã€ã«ã¹ç ç©¶ã«ã€ããŠåœé²ç·çã®DARPAïŒåœé²é«çç ç©¶èšç»å±ïŒããã°ã©ã ãæ¬ºãããšãã ããšããã
ãµãã«ãŒã¯ããæžããŠããïŒ
ãDARPAã¯ãããã€ãã®ç ç©¶ãå±éºãªæ©èœç²åŸç ç©¶ãå«ãã§ãããšããŠããã®ææ¡ãåŽäžãããæã ã¯ãDEFUSEææ¡ã®èçš¿ããããŠã€ã«ã¹åŠè ãæŠæŒ¢ãŠã€ã«ã¹åŠç ç©¶æã§ãããã®ç ç©¶ãèšç»ããŠããããšãç¥ã£ãŠãããã
ã以åã®å£°æã§ããŠã€ã«ã¹åŠè ãšç§åŠã©ã€ã¿ãŒã¯ãDEFUSEã§è°è«ãããæ©èœç²åŸç ç©¶ã¯ããŒã¹ã«ãã©ã€ã倧åŠïŒUNCïŒã®ã©ã«ãã»ããªãã¯ã®ç 究宀ã§è¡ãããã¯ãã§ãããæŠæŒ¢ãŠã€ã«ã¹ç ç©¶æã®ç³æ£åïŒShi ZhengliïŒã®ç 究宀ã§ã¯è¡ãããªããšæèšãããã
ãç§ãã¡ãç¥ã£ãŠããããã«ããã³ãããã¯ã¯æŠæŒ¢ã§å§ãŸã£ããã
ãµãã«ãŒã¯ãŸãããDEFUSEææ¡ã®åæã®èçš¿ã§ãããŒã¿ãŒã»ãã¹ã¶ãã¯ã¯UNCã®ã©ã«ãã»ããªãã¯ãšæŠæŒ¢ã®ç³æ£åã«å¯ŸããŠããã¡ã©SARSãŠã€ã«ã¹ãäœè£œããä»äºã®äžéšã¯æŠæŒ¢ã§è¡ããããšã³ã¡ã³ãããããšè¿°ã¹ãŠããããåŸã«æŠæŒ¢ãšç³æ£åãšã®é¢é£ãã軜èŠãããããšããã
ãã®åŸãããµã€ãšã³ã¹ãèªã®ãžã§ã³ã»ã³ãŒãšã³ã®ãããªãžã£ãŒããªã¹ãã¯ãDEFUSEã®ç ç©¶ãšCOVID-19ç 究宀æµåºèª¬ãšã®é¢é£æ§ãå ¬ã«åŠå®ããããšããããµãã«ãŒã«ããã°ãã³ãŒãšã³ã¯DEFUSEç ç©¶ãšãã®è³éæäŸè ã«é¢ãã圌ã®è³ªåã«ã€ããŠããåœæ å ±ãã宣äŒããŠãããšãã€ãã¿ãŒã§å ¬ã«éé£ããããšãããã
å¥ã®äŸã§ã¯ãããµã€ãšã³ã¹ãèªã®ç·šéé·Hã»ããŒã«ãã³ã»ãœãŒããã瀟説ã§DEFUSEå®éšã¯ãã»ãšãã©è åšãšã¯ãªããããæŠæŒ¢ã§ã¯èµ·ããããªãã£ããšäž»åŒµãããç§åŠçå šäœã欺ããããšè¿°ã¹ãã
ãœãŒãã¯UNCåºèº«ã§ãã©ã«ãã»ããªãã¯ã®ç ç©¶ãå«ã倧åŠã®ç ç©¶ãç£ç£ããŠããããœãŒãã¯ãåœé£å€§åŠãåºç¯ãªåŠè¡äžæ£ã§æçºãããåŸãç·é·ã®è·ãèŸããã
ãå¥ã®åãæããã«ãªã£ãããæŠæŒ¢ã§ãã§ã«ãã¡ã©ç ç©¶ãããŠãããããæŠæŒ¢ã§ãã®ç ç©¶ãããã€ããã ã£ããšããäºå®ãæããã«ãªã£ãããã§ã¯ãªãããšãµãã«ãŒæ°ã¯ããã£ãã§ã³ããŒãçŽã«èªã£ãã
ãµãã«ãŒæ°ã¯ããã®ãããªäŸã¯ããµã€ãšã³ã¹ã»ã©ã€ã¿ãŒãšãããžã£ã³ã«ã®å žåçãªãã®ã§ãç§åŠã«è åšãäžãããããªã¡ãã»ãŒãžãçºãããšããã®ç§åŠè ãã¡ã®ãšããã«é§ã蟌ãã§å®åæãåŒçšãããããæã¡å£ãããšæžããŠããã
ãDEFUSE婿éã«ã€ããŠç§åŠè ãã¡ãæã ã«èªã£ãããšã¯ãã»ãšãã©çå®ã§ã¯ãªãã£ãããšãããã£ããããŠã€ã«ã¹åŠè ãã¡ã¯æŠæŒ¢ã§å±éºãªãŠã€ã«ã¹ç ç©¶ãè¡ãããšãèšç»ããé£éŠæ¿åºã«åãã€ããŠè³éãåŸãããããŠãæŠæŒ¢ã§ãã³ãããã¯ãå§ãŸã£ãåŸããã®æå³ã«ã€ããŠç§ãã¡ã«åãã€ããã
ããµã€ãšã³ã¹ã»ã©ã€ã¿ãŒã¯ãããªããä»ã®ã¢ã¡ãªã«åœæ°ã«ãããã®åãå¢å¹ ããããã
ããã§ã€ã¹ããã¯ã¯ãå®éšå®€ã®äºæ ã«ã€ããŠè©±ãããšãå¶éããŸããã"æŠæŒ¢ã®ç 究宀ããåºãã¯ãããªã "ãšããè€æ°ã® "ãã¡ã¯ããã§ã㯠"ããã£ããã
ããããç 究宀ããã®æµåºãç€ºãæ å ±ãå¢ããã«ã€ãã以åã¯ç 究宀æµåºèª¬ãåŠå®ããŠããã³ãŒãšã³ã®ãããªã©ã€ã¿ãŒããä»ã§ã¯åŸéããŠããããšãµãã«ãŒã¯èšãã
ãé èœå·¥äœã«é¢äžãã圌ãã®å€ãã¯ãæ¥ããããããã®ã§ããã€ãã¿ãŒããéããŠãããã
ã圌ããééã£ãã®ã¯ããã ãã§ã¯ãªãããã¹ã¯ãã¯ã¯ãã³ãããã¯ããŠã³ãªã©ã圌ããæžããå€ãã®ããšãééã£ãŠãããã
ã圌ãã¯ããã¯ãèªåãã¡ãã·ããªãªãã³ã³ãããŒã«ã§ããªããªã£ããšããäºå®ã«èããããªãã®ã ããããŠãèªåãã¡ã®ã·ããªãªãå¹ãé£ãã§ããäºå®ãç®ã®åœããã«ããŠãããã
ãã®ããšã¯ãå°æ¥ã®ãã³ãããã¯ïŒäžçç倧æµè¡ïŒãžã®åããšããç¹ã§ãéèŠãªæå³ãæã£ãŠããããšãµãã«ãŒã¯èšãïŒ
ãå°æ¥ã®ç«çœãé£ãæ¢ããæ¹æ³ãèããæåã®æ¹æ³ã¯ãç§ãã¡ã察åŠããŠããç«çœãã©ã®ããã«å§ãŸã£ãããçè§£ããããšã§ãããã®ããã«ãæ¶é²æ€æ»å®ãåºåããäœãç«å ãšãªã£ãããæ€æ»ããã®ã§ããã...
ããã³ãããã¯ã®ç ç©¶ãåãã ãåœåãããç 究宀ã§ã®äºæ ã®å¯èœæ§ãåŠå®ãã軜èŠããããšãã詊ã¿ãçµ¶ããªãã£ããã